Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Four CRISPR Companies Reach Agreement in Patent Case

XTALKS VITALS NEWS

DNA

These four companies make up one side of the CRISPR patent interference case, which will decide who owns the licensing rights to the exciting new gene editing technique.

Share this!

December 20, 2016 | by Sarah Hand, M.Sc.

Four companies focusing on CRISPR gene editing have agreed to form an intellectual property (IP) alliance. CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics have all agreed to honor their respective licensing deals with the co-owners of the IP, including the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna.

“We are pleased that we have come to this global agreement with Intellia, Caribou, ERS and the co-owners and other licensees of this foundational CRISPR/Cas9 technology IP,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. “We believe that the Charpentier-University of California-Vienna IP estate constitutes the foundational IP in the CRISPR/Cas9 editing space. Intellia, CRISPR Therapeutics, Caribou, and ERS view this agreement as enhancing the efforts to protect our shared intellectual property rights and support the ongoing development of our product candidates, as well as those of our corresponding partners and licensees.”



These four companies make up one side of the CRISPR patent interference case, which will decide who owns the licensing rights to the exciting new gene editing technique. The agreement ensures that all four companies respect each other’s global rights to the technology.

Jennifer Doudna and Emmanuelle Charpentier are credited with the co-discovery that the CRISPR-Cas9 system could be applied to gene editing in mammalian cells. Since then, the two have independently founded CRISPR-focused biotechs, with Doudna founding Caribou and Intellia, and Charpentier founding CRISPR and ERS.

“Through this agreement, we are ensuring alignment in our efforts to protect and prosecute the foundational CRISPR/Cas9 discoveries made by Dr. Doudna, Dr. Charpentier, and their teams, which have transformed the genomics field and unleashed new therapeutic possibilities,” said Nessan Bermingham, CEO and founder, Intellia Therapeutics. “This strengthens Intellia's IP position as we continue forging ahead with the discovery and development of therapies for patients worldwide.”


Keywords: CRISPR, Gene Editing, Intellectual Property


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News


Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News


Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.